General Court 22 March 2018, Case T-80/16: Judgment of the General Court of 22 March 2018 — Shire Pharmaceuticals Ireland v EMA (Medicinal products for human use — Validation of an application for designation as an orphan medicinal product — Significant benefit — EMA decision refusing to validate an application for designation as an orphan medicinal product — Article 3(1)(b) and Article 5(1), (2) and (4) of Regulation (EC) No 141/2000)
Also known as
European Union · · · 22-03-2018
14.5.2018 EN Official Journal of the European Union C 166/27 Judgment of the General Court of 22 March 2018 — Shire Pharmaceuticals Ireland v EMA (Case T-80/16) (1) ((Medicinal products for human use - Validation of an application for designation as an orphan medicinal product - Significant benefit - EMA decision refusing to validate an application for designation as an orphan medicinal product -
Read the full text
This document is published by eur-lex.europa.eu.
Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.
Sign in to Moonlit